lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Roth IRA!
If you're not selling today then tomorrow only brings additional opportunity.
No doubt in my mind that organized crime of Sicilian and Russian heritage are involved in manipulating NWBO stock. The question remains how long will it take for Cofer Black to strike?
MHRA already approved DCVax when they approved PIP and MIA. You are full of 🐎 💩!
Lots of 🐎 💩 in your posts per usual.
Bureaucracy can move faster or slower than their standard operating procedures dictate given many variables like institutional capacity, resources, and priority.
Covid 19 vaccines and treatments were fast tracked by NICE.
I maintain NICE will issue their assessment concurrently with MAA approval.
Retail shareholders are not going to accept a buyout at $10. I will be there in person to argue against that at any shareholder meeting while I think many would agree to fight such a hostile takeover.
I believe management would reject such an insult. So the only way this horrible $10 deal would be considered could be through hostile bid.
Right after we win the European Combination Patent we hear nothing but doomsayers. It's gaslighting. They're not getting my shares while my GTC limit buy order remains ready to be filled.
In reality MHRA can refer our MAA to FDA, Health Canada, and EMA under Project Orbis while again NICE does not need to wait for MHRA to sign off on MAA before finalizing their recommendations which can be released concurrently with MAA approval.
The idea that bureaucrats, working for one government on a shared mission to address a terminal brain cancer which killed a prominent MP, are completely uncoordinated here on this matter is insane. I believe private insurance reimbursement in US will take much longer than NHS!
As of 2023 NICE told me:
In reality NHS will reimburse up to 100K per QALY for rare and orphan diseases. I expect NICE will reimburse DCVax at 150K though I would be happy with 80-100K for UK market.
NICE assessment can begin before MAA submission if MAA submission will occur during NICE appraisal. I expect NICE will recommend reimbursement concurrently with MHRA approval. Both will occur Q2 2024 in my opinion though March possible if we get Phase 1 MHRA approval of DCVax.
CAR-T were approved with worse data as were TIL. There's 0% chance regulators require another trial nor would the company ever be sold for $20.
Thank you for that detailed response which showcases the many reasons why it's great to be a Northwest Biotherapeutics shareholder!
Why would Merck help Northwest Biotherapeutics erect a moat around their castle?
🤣
Smells like a bidding war.
Linda Powers yet again delivers a huge win. This month of February has been quite amazing. I wonder what March will bring?
I agree buyout remains highly probable outcome.
DCVax superior. Thank you for the explanation!
Yep I am looking forward to March!
Market makers are required to provide liquidity so they must often take the other side of a trade. If they themselves spoof to move the price then the implications are the same regardless whether they do it on behalf of a third party.
They're clearly able to modify pleadings to meet adopted R&R for loss causation.
Amendment guaranteed
Google says you're wrong. I will believe Google over you all day every day.
No, biotechnology companies typically do not issue press releases directly on the acceptance or validation of their drug submission applications to regulators.
Here's why:
Regulatory process is confidential: The review process by regulatory agencies (like the FDA in the US or EMA in Europe) is confidential. Companies are not informed about the details of the review or even when it begins. Sharing such information prematurely could violate regulations and jeopardize the application.
Acceptance/Validation isn't a guarantee: Acceptance or validation of the application simply means that the regulators have deemed it complete and ready for review. It's not a guarantee of approval, and publicizing it could raise false expectations.
Focus on milestones: Companies typically issue press releases when they reach significant milestones in the development process, such as the completion of clinical trials, submission of the application, or receiving approval. This showcases progress and potential impact.
However, there are some nuances to consider:
Companies might mention submission/acceptance in broader announcements: They might briefly mention submission or acceptance as part of a larger press release about the development program or company performance, without focusing solely on that step.
Positive updates after review: If the regulatory agency provides positive feedback during the review process, like agreeing to a faster evaluation timeline, the company might share that in a press release, emphasizing the potential progress.
Overall, while companies prioritize transparency and communication, they are cautious about disclosing information during the confidential regulatory review process. They focus on sharing major milestones and achievements linked to approval rather than the internal acceptance/validation steps.
No problem or disagreement.
An RFI may come. It's not a matter of process which occurs with all applications. Phase I approvals in 80 days or less are possible.
Many of my friends as well as immediate and extended family own Northwest Biotherapeutics.
I believe it will be a strong amended complaint given the courts have already concluded that spoofing occurred.
You are wrong per usual.
I agree 1000%!
There are other defendants besides Citadel.
If this deliberative process means executives must curtail their monthly supply of hookers and blow I consider that a small victory worth celebrating.
Data shows otherwise. You obviously haven't performed any due diligence into this company.
Future columnist for Readers Digest wrong all of the time.
I doubt you own any shares in this fantastic company which defeated Glioblastoma.
I wouldn't expect Posner to hand over proprietary information unless asked nor would she commit perjury by fabricating the existence of the forumula!
We will see it provided in my opinion in the amended complaint which then survives the motion to dismiss.
I agree that we will lose if we can't provide the forumula. It's highly unlikely that Posner put her name on federal court filings which contain fabricated arguments. That would be perjury.
They have the forumula which was likely created by outside experts. There's no reason for Posner to give this evidence at MTD filings unless requested as this only allows defendants time to undermine it with their own experts after we survive MTD. Why would we make it easier for defense council? Obviously Poser's being strategic.
Posner correctly interrogated the court to determine what would need to be pled in this novel case. I believe she's being strategic while we already met other elements needed to survive loss causation.
If the process continues for another several months that's great as it ties up defendants in legal bills which we are not paying. The outcome still has a good probability of being legal settlement once we survive MTD.